Last update Sept. 4, 2022
Antiemetic and antinauseous used in the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy, radiotherapy and in the postoperative period. Intravenous administration in one or two daily doses.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its pharmacokinetic data do not allow a good prediction of its possible excretion in breast milk, since while its low protein binding, low molecular weight and high pKA would facilitate it (Pistilli 2013), its very large volume of distribution would make it difficult.
Although some author considers it probably compatible (Mahadevan 2006), until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable (Pistilli 2013), especially during the neonatal period and in the event of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM